MIM
CASC

Monashee Investment Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Monashee Investment Management’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-150,000
Closed -$557K – 140
2017
Q2 		$557K Buy
+150,000
New +$595K 0.24% 69
2015
Q2 		– Sell
-33,333
Closed -$326K – 118
2015
Q1 		$326K Buy
+33,333
New +$327K 0.2% 64

Other funds holding CASC

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
SH
Sandia Holdings Greenwich, Connecticut $213M AUM 29.35% 1-Year Est. Return

Monashee Investment Management's CASC Position: Q3 2017 in Review

Monashee Investment Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q3 2017, closing a stake of 150,000 shares — an estimated $557K sold.

Monashee Investment Management first reported a position in CASC in Q1 2015 and held it in 2 quarters. The position peaked at $557K in Q2 2017. 79 funds tracked by Wall St. Rank hold CASC as of Q3 2017.

  • Monashee Investment Management reported no remaining Cascadian Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Monashee Investment Management sold 150,000 Cascadian Therapeutics, Inc. shares in Q3 2017, an estimated $557K.
  • Monashee Investment Management first reported a position in Cascadian Therapeutics, Inc. in Q1 2015 and held it in 2 quarters.
  • Monashee Investment Management's Cascadian Therapeutics, Inc. position peaked at $557K in Q2 2017.
  • 79 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q3 2017.

Based on Monashee Investment Management's 13F filing for Q3 2017, filed 13 Nov 2017.